CO2024003723A2 - Compuestos de imidazopiridazina inhibidores de il-17 - Google Patents
Compuestos de imidazopiridazina inhibidores de il-17Info
- Publication number
- CO2024003723A2 CO2024003723A2 CONC2024/0003723A CO2024003723A CO2024003723A2 CO 2024003723 A2 CO2024003723 A2 CO 2024003723A2 CO 2024003723 A CO2024003723 A CO 2024003723A CO 2024003723 A2 CO2024003723 A2 CO 2024003723A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitors
- compounds
- imidazopyridazine compounds
- imidazopyridazine
- syndrome
- Prior art date
Links
- 150000005233 imidazopyridazines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248566P | 2021-09-27 | 2021-09-27 | |
| US202163273422P | 2021-10-29 | 2021-10-29 | |
| US202263367546P | 2022-07-01 | 2022-07-01 | |
| PCT/US2022/077001 WO2023049887A1 (en) | 2021-09-27 | 2022-09-26 | Imidazopyridazine il-17 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024003723A2 true CO2024003723A2 (es) | 2024-04-18 |
Family
ID=83692741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0003723A CO2024003723A2 (es) | 2021-09-27 | 2024-03-22 | Compuestos de imidazopiridazina inhibidores de il-17 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12173007B2 (https=) |
| EP (1) | EP4408847A1 (https=) |
| JP (1) | JP2024536869A (https=) |
| KR (1) | KR20240082369A (https=) |
| AU (1) | AU2022349687A1 (https=) |
| CA (1) | CA3233408A1 (https=) |
| CL (1) | CL2024000867A1 (https=) |
| CO (1) | CO2024003723A2 (https=) |
| DO (1) | DOP2024000051A (https=) |
| IL (1) | IL311751A (https=) |
| JO (1) | JOP20240059A1 (https=) |
| MX (1) | MX2024003772A (https=) |
| PE (1) | PE20240935A1 (https=) |
| TW (1) | TW202330530A (https=) |
| UY (1) | UY39958A (https=) |
| WO (1) | WO2023049887A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311751A (en) | 2021-09-27 | 2024-05-01 | Janssen Pharmaceutica Nv | IL-17 imidazopyridazine inhibitory compounds |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| CN120731202A (zh) * | 2023-01-30 | 2025-09-30 | 戴斯阿尔法公司 | 基于苯并咪唑和氮杂-苯并咪唑的il-17a调节剂及其用途 |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024215597A1 (en) * | 2023-04-11 | 2024-10-17 | Dice Alpha, Inc. | Substituted 6-imidazopyridazine il-17a modulators and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752400B (zh) | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| PE20230469A1 (es) | 2020-04-30 | 2023-03-14 | Janssen Pharmaceutica Nv | Imidazopiridazinas como moduladores de il-17 |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| IL311751A (en) | 2021-09-27 | 2024-05-01 | Janssen Pharmaceutica Nv | IL-17 imidazopyridazine inhibitory compounds |
| CN116143777A (zh) | 2021-11-04 | 2023-05-23 | 四川海思科制药有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
-
2022
- 2022-09-26 IL IL311751A patent/IL311751A/en unknown
- 2022-09-26 WO PCT/US2022/077001 patent/WO2023049887A1/en not_active Ceased
- 2022-09-26 TW TW111136301A patent/TW202330530A/zh unknown
- 2022-09-26 PE PE2024000594A patent/PE20240935A1/es unknown
- 2022-09-26 EP EP22790174.1A patent/EP4408847A1/en active Pending
- 2022-09-26 CA CA3233408A patent/CA3233408A1/en active Pending
- 2022-09-26 UY UY0001039958A patent/UY39958A/es unknown
- 2022-09-26 US US17/935,360 patent/US12173007B2/en active Active
- 2022-09-26 KR KR1020247013352A patent/KR20240082369A/ko active Pending
- 2022-09-26 AU AU2022349687A patent/AU2022349687A1/en active Pending
- 2022-09-26 MX MX2024003772A patent/MX2024003772A/es unknown
- 2022-09-26 JP JP2024518884A patent/JP2024536869A/ja active Pending
-
2024
- 2024-03-14 DO DO2024000051A patent/DOP2024000051A/es unknown
- 2024-03-22 CO CONC2024/0003723A patent/CO2024003723A2/es unknown
- 2024-03-25 CL CL2024000867A patent/CL2024000867A1/es unknown
- 2024-03-26 JO JOJO/P/2024/0059A patent/JOP20240059A1/ar unknown
- 2024-10-04 US US18/906,207 patent/US20250109137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230143050A1 (en) | 2023-05-11 |
| CL2024000867A1 (es) | 2024-09-23 |
| WO2023049887A1 (en) | 2023-03-30 |
| AU2022349687A1 (en) | 2024-05-16 |
| IL311751A (en) | 2024-05-01 |
| EP4408847A1 (en) | 2024-08-07 |
| PE20240935A1 (es) | 2024-04-30 |
| CA3233408A1 (en) | 2023-03-30 |
| MX2024003772A (es) | 2024-06-19 |
| US12173007B2 (en) | 2024-12-24 |
| US20250109137A1 (en) | 2025-04-03 |
| TW202330530A (zh) | 2023-08-01 |
| KR20240082369A (ko) | 2024-06-10 |
| JOP20240059A1 (ar) | 2024-03-26 |
| JP2024536869A (ja) | 2024-10-08 |
| DOP2024000051A (es) | 2024-11-15 |
| UY39958A (es) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022017072A2 (es) | Imidazopiridazinas como moduladores de il-17 | |
| CO2024003723A2 (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| UY39957A (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| MX2022013650A (es) | Imidazopirimidinas como moduladores de il-17. | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MX2024009943A (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| DE602007014186D1 (de) | Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer | |
| MX2012001654A (es) | Metodos para usar moduladores de c-met. | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| UY30628A1 (es) | Inhibidores de metaloproteasas de matriz | |
| MX389545B (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| DOP2014000037A (es) | Inhibidores de la enzima activadora de nedd8 | |
| MX2022006176A (es) | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| ECSP19019613A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| CL2023000857A1 (es) | Inhibidores line-1 para tratar la enfermedad | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| CL2025000078A1 (es) | Formas sólidas de un derivado de triazina como modulador cbl-b | |
| CL2022002989A1 (es) | Imidazopiridazinas como moduladores de il-17. |